Holen Sie sich die Stockscreener-App
12.06
1.94%
0.23
Handel nachbörslich:
12.05
-0.010
-0.08%
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Is Intellia Therapeutics Inc. a good long term investmentRapidly expanding wealth - Jammu Links News
What drives Intellia Therapeutics Inc. stock priceTriple returns potential - Jammu Links News
What analysts say about Intellia Therapeutics Inc. stockOverwhelming financial success - Jammu Links News
Intellia Therapeutics: A High-Volatility, High-Reward Play in the CRISPR Revolution - AInvest
With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At ‘Buy’ (NTLA) - Seeking Alpha
Intellia Therapeutics Inc. Stock Analysis and ForecastHigh-profit capital plays - Jammu Links News
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer? - TipRanks
Intellia Faces The Biotech Balancing Act As Shares Slide - Finimize
ATTR Amyloidosis Pipeline 2025: Groundbreaking Clinical - openPR.com
Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B - TipRanks
Intellia Therapeutics (NTLA) Soars 9.08% on Phase III Trial - AInvest
Possible Bearish Signals With Intellia Therapeutics Insiders Disposing Stock - simplywall.st
Intellia Therapeutics (NTLA) Receives a Buy from RBC Capital - The Globe and Mail
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Gene Editing Leader Intellia Expands Team with 23,800 Share RSU Grant Package - Stock Titan
Intellia Gains 29.8% in a Month: How Should You Play the Stock? - Nasdaq
Intellia Therapeutics Reports Inducement Grants under Nasdaq Lis - GuruFocus
Insider Sell: Eliana Clark Sells Shares of Intellia Therapeutics Inc (NTLA) - GuruFocus
Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data - Insider Monkey
Insider Sell Alert: Jesse Goodman Sells Shares of Intellia Thera - GuruFocus
The Best Biotech Stocks to Buy - Morningstar
Intellia Therapeutics gets FDA RMAT status for its heart disorder treatment - MSN
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? - Yahoo Finance
Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress - Insider Monkey
Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress. - Yahoo Finance
Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely? - Yahoo Finance
Intellia Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year - Investing.com
From Now to 2032: Unpacking the Genome Editing Market's - openPR.com
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView
Intellia Reports Positive Three-Year Follow-up Data from Phase 1 CRISPR Trial in Hereditary Angioedema - CRISPR Medicine News
Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential - Yahoo Finance
Intellia’s three-year HAE treatment data shows durability, Citizens JMP says - Investing.com Canada
FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction - BioPharma Dive
Intellia Therapeutics (NTLA) Receives Reiterated Buy Rating with Stable Price Target | NTLA Stock News - GuruFocus
Intellia Therapeutics Announces Positive Phase 1 Trial Data - TipRanks
Intellia Therapeutics Says Potential Hereditary Angioedema Treatment Reduces Attacks - MarketScreener
Intellia Therapeutics Announces Positive Three-Year Data - GlobeNewswire
Intellia Therapeutics Announces Positive Three-Year Data from Ph - GuruFocus
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewswire
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewswire Inc.
Revolutionary Gene Therapy Eliminates HAE Attacks for 2 Years: Breakthrough Phase 1 Trial Results - Stock Titan
Intellia Therapeutics’ SWOT analysis: gene editing stock faces pivotal year - Investing.com
Intellia Therapeutics Holds Annual Stockholders’ Meeting - TipRanks
California State Teachers Retirement System Grows Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - Defense World
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA Stock News - GuruFocus
Intellia Therapeutics Expands CRISPR Team: 33,600 RSUs Granted to New Leadership - Stock Titan
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting - mx.advfn.com
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% - sharewise
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - TradingView
Intellia Therapeutics (NASDAQ:NTLA) Given New $54.00 Price Target at Canaccord Genuity Group - Defense World
Intellia Therapeutics (NTLA) Price Target Adjusted by Canaccord Genuity | NTLA Stock News - GuruFocus
(NTLA) Investment Report - news.stocktradersdaily.com
Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Up - GuruFocus
Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Updates | NTLA Stock News - GuruFocus
0.59%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):